If you have been reading about GHRH analog and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-11. Numbers and descriptions here follow the published literature rather than marketing material.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Chain length | 29 amino acids | Based on the GRF(1-29) fragment |
| Appearance | White to off-white lyophilized powder | Common research supply form |
| Solubility | Soluble in water and aqueous buffers | Powder requires reconstitution before use |
| Typical storage | −20 °C or below | Kept away from light and moisture |
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Kipa-Williams enjoyed working with Samson, as they got along well and he believed that showed on-screen as Ari and Mia reconcile. He also praised Barrett and explained how they got the chance to explore their characters' histories together, saying "you'll get to see a softer side of Ari in the way that Sam plays her character. And I think people will be surprised at the father figure that he has forgotten he is, or was." The first test of Ari and Mia's new relationship is his involvement with a criminal gang headed up by Paul (Jack Finsterer), which leads to the kidnapping of Chloe, Nikau, Bella, and Ryder Jackson (Lukas Radovich). Mia decides to leave the Bay with Chloe and tells Ari that she regrets letting him back into her life. Kipa-Williams commented that "Ari is heartbroken – he's faced with losing the love of his life." He sympathised with Mia, who is angry about her daughter being kidnapped. He also pointed out that Mia thought Ari had changed, so it "pains" her to think that he is still the same man who could end up in prison again. As Ari is walking along the road, he calls Chloe before she leaves town, and is struck by a car driven by Paul who then speeds off. Kipa-Williams said Ari is "blindsided" by the attack and described it as "a ruthless hit-and-run". Ari suffers multiple injuries and has to be placed in a medically induced coma due to a bleed on the brain. Following Ari's recovery, writers scripted a pregnancy for Mia after the couple agree to try for a baby.
=== Civilian government negotiations === In May 2019, al-Burhan's first international trip was to Egypt to meet Abdel Fattah el-Sisi. His second visit was to the United Arab Emirates, where he met with the de facto ruler of the United Arab Emirates, Mohamed bin Zayed Al Nahyan. Iyad el-Baghdadi, a human rights activist who became famous during the Arab Spring, later interpreted these visits (together with a visit by TMC deputy leader Hemedti to Mohammed bin Salman in Saudi Arabia) as encouragements for the TMC to cancel negotiations with the opposition. This comment by Iyad el-Baghdadi and recent developments and his ties to the Egyptian brotherhood which he established long ago when he studied in Egypt has led to the popular belief that al-Burhan has no interest to lead Sudan to a democratic and civilian state. Despite his promise to establish a civilian government by February 2021 as demanded by numerous protesters, his group seems to consistently isolate the civilian government led by Hamdok in key government decisions.
=== FDA Warning for illegal marketing === On April 17, 2017, LifeVantage was issued a warning letter by the U.S. Food and Drug Administration (FDA) regarding illegal advertising claims on the company's websites suggesting that Protandim can play a role in helping to cure various ailments, including cancer and diabetes. The claims were deemed to be in violation of Section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. § 321(g)(1)(B)].
=== Brand names === Spironolactone is marketed under various brand names throughout the world. The original brand name of spironolactone is Aldactone. Other brand names include Aldactone-A, Berlactone, CaroSpir, Espironolactona, Espironolactona Genfar, Novo-Spiroton, Prilactone (veterinary), Spiractin, Spiridon, Spirix, Spiroctan, Spiroderm (discontinued), Spirogamma, Spirohexal, Spirolon, Spirolone, Spiron, Spironolactone Actavis, Spironolactone Orion, Spironolactone Teva, Spirotone, Tempora (veterinary), Uractone, Uractonum, Verospiron, and Vivitar. Spironolactone is also formulated in combination with a variety of other medications, including with hydrochlorothiazide as Aldactazide, with hydroflumethiazide as Aldactide, Lasilacton, Lasilactone, and Spiromide, with altizide as Aldactacine and Aldactazine, with furosemide as Fruselac, with benazepril as Cardalis (veterinary), with metolazone as Metolactone, with bendroflumethiazide as Sali-Aldopur, and with torasemide as Dytor Plus, Torlactone, and Zator Plus.
Sources: en.wikipedia.org
=== Gas chromatography/mass spectroscopy === Gas chromatography (GC) and mass spectrometry (MS) are commonly used to detect and identify sugiol in a sample. GC/MS is highly specific and sensitive and allows for identification of a wide range of analytes. After extraction from the original sample, which could be the resin of a living plant, or a preserved rock sample, the sample can be ionized and the components identified through their representative spectra. Analysis of fragmentation patterns can also be used to identify a compound by connecting each peak in the mass spectra to the masses of significant fragmentation products of the molecule, as well as the molecular ion, which is the largest significant peak in the spectra. When identifying sugiol in a sample, full-scan monitoring is commonly used to scan the full range of masses from 50 to 650 Da. This allows for detection of compounds with a wide range of molecular masses when attempting to make an identification based on chemical composition. Electron impact ionization is also commonly used to break apart and ionize the samples before they are passed to the mass spectrometer. The molecular ion peak for sugiol appears as a small peak at an m/z ratio of 300.2084. The largest peak in the mass spectra appears at a m/z ratio of 285.1849, and corresponds to a fragmentation product with a formula of C19H25O2. This fragmentation product has one less ring and an H2O molecule bound to the newly open carbon chain.
George Speri Sperti (January 17, 1900, Covington, Kentucky – April 29, 1991, Cincinnati, Ohio) was an Italian-American who invented Preparation H hemorrhoid medication. He also invented the Sperti Ultraviolet Lamp, Aspercreme for pain relief, and KVa Power Meter.
=== Efficacy === There is an average 52% decrease in inflammatory acne lesions by week 12. The combination is less effective than benzoyl peroxide/salicylic acid after short-term treatment of two to four weeks, but the two treatments showed similar effectiveness after ten to twelve weeks.
Sources: en.wikipedia.org
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.
DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.
Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.